Leukotriene-Receptor Inhibition for the Treatment of Systemic Mastocytosis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
To the Editor: Systemic mastocytosis is an uncommon and potentially misdiagnosed condition. Its hallmark is the accumulation and abnormal proliferation of mast cells in various tissues. A two-month-old boy was referred to our facility with numerous bullae on the skin and unilateral periorbital cellulitis. The child was inconsolable, and his skin lesions, which had been present since birth, progressed into subcutaneous nodules, plaques, and tumors, which were excoriated. He had hepatomegaly and wheezing. Findings on examination of biopsy specimens of the skin and bone marrow were consistent with the diagnosis of systemic mastocytosis. There were no bony lesions, and there . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Casassus, P., Caillat‐Vigneron, N., Martin, A., Simon, J., Gallais, V., Beaudry, P., Eclache, V., Laroche, L., Lortholary, P., Raphaël, M., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03944.x · Cited by 157
Bouchelouche, K., Nordling, J., Hald, T., & Bouchelouche, P. N. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65663-7 · Cited by 59
Treatment of mastocytosis: pharmacologic basis and current concepts
Marone, G., Spadaro, G., Granata, F., & Triggiani, M. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00039-x · Cited by 55
Cited by
Weiler, C. R., Austen, K. F., Akin, C., Barkoff, M. S., Bernstein, J. A., Bonadonna, P., Butterfield, J. H., Carter, M., Fox, C. C., Maitland, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.023 · Cited by 123
“These medications might work best in conjunction with H1R antihistamines, being most efficacious for dermatologic symptoms.(122,123) PGD2.”
BackgroundSystemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Gotlib, J., Gerds, A. T., Bose, P., Castells, M. C., Deininger, M. W., Gojo, I., Gundabolu, K., Hobbs, G., Jamieson, C., McMahon, B., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0088 · Cited by 106
Pardanani, A. (2013) · Blood · doi:10.1182/blood-2013-01-453183 · Cited by 101
“Leukotriene antagonists can be useful as adjunctive therapy in patients with suboptimal response to first-line antimediator drugs, and may be steroid-sparing in this role.(33) Flushing can be severe/subjectively distressing, and unresponsive to antihistamines; aspirin can be useful in this setting, likely due to its a…”
BackgroundMast cells in gastrointestinal disease.
Ramsay, D. B., Stephen, S., Borum, M. L., Voltaggio, L., & Doman, D. B. (2010) · PubMed · Cited by 106
Receptors, cells and circuits involved in pruritus of systemic disorders
Kremer, A. E., Feramisco, J. D., Reeh, P. W., Beuers, U. H., & Elferink, R. P. J. O. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.02.007 · Cited by 106
Metadata
- Authors
- Tolar, J., Tope, W. D., & Neglia, J. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-02-12
- Volume
- 350
- Issue
- 7
- Pages
- 735-736
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2072949862
- Cited by
- 70
- References
- 3
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 7 · 2018: 2 · 2017: 3 · 2016: 6 · 2015: 3 · 2014: 6 · 2013: 6 · 2012: 1
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Hematology › Histiocytic Disorders and Treatments
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Keywords
- systemic mastocytosis, leukotriene receptor antagonists, mast cell proliferation, bullae, periorbital cellulitis, hepatomegaly, wheezing, pediatric patients, mastocytoma
- MeSH terms
- Acetates, Anti-Inflammatory Agents, Cyclopropanes, Drug Therapy, Combination, Humans, Infant, Male, Prednisone, Quinolines, Sulfides, Leukotriene Antagonists, Mastocytosis, Systemic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Leukotriene-Receptor Inhibition for the Treatment of Systemic Mastocytosis. https://app.cochat.ai/papers/10.1056/nejm200402123500723
- The paper
- Tolar, J., Tope, W. D., & Neglia, J. P. (2004). Leukotriene-Receptor Inhibition for the Treatment of Systemic Mastocytosis. New England Journal of Medicine. https://doi.org/10.1056/nejm200402123500723
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.